ClinicalTrials.gg
RecruitingNCT05434234Updated Jun 22, 2026

A Study of YL201 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of YL201 and YL201 in Advanced Solid Tumor, sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.. Recruiting at 45 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
312
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2).

Part 1 will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors unresponsive to currently available therapies or for whom no standard therapy is available.

Part 2 will include patients with selected advanced solid tumor types enrolled at the MTD/RED(s), to better define the safety profile and evaluate the efficacy of YL201.

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Antibody-drug conjugate
03

In context

Lead sponsor

MediLink Therapeutics (Suzhou) Co., Ltd. is the lead sponsor of 23 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Informed of the trial before the start of the trial and voluntarily sign their name and date on the ICF
  • Aged ≥18 years
  • performance status (ECOG PS) of 0 or 1
  • Adequate organ and bone marrow function
  • Female patients of must agree to use a highly effective form of and not donate, or retrieve for their own use, ova from the time of screening and throughout the study period, and for at least 5 months after the last dose of atezolizumab or 6 months after the last dose of YL201, whichever is later. Male patients must agree to use a highly effective form of contraception and not freeze or donate sperm from the time of screening and throughout the study period, and for at least 6 months after the last dose of YL201.
  • of ≥3 months
  • Able and willing to comply with protocol visits and procedures
  • Have at least 1 evaluable tumor lesion according to (RECIST) version 1.1.
  • confirmed diagnosis of an advanced solid tumor (SCLC, mCRPC, ESCC and NSCLC are preferred) for which standard treatment had proven to be ineffective or intolerable, or no standard treatment is available. For ES-SCLC patients in Arm C: no prior anti-cancer treatment

Exclusion criteria

Exclusion Criteria:

  • Concurrent enrollment in another clinical study, unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study
  • Prior systemic anticancer treatment including chemotherapy, molecular -targeted therapy, hormonal therapy, immunotherapy, or biological therapy within 3 weeks before the first dose of study drug (use of oral fluorouracil [eg, tegafur and capecitabine] or small molecular-targeted therapy within 2 weeks or 5 half-life periods [whichever is shorter]before the first dose; use of mitomycin or nitrosoureas within 6 weeks before the first dose; use of herbal medicine with antitumor indications or nonspecific immunomodulators [eg, thymosin, interferon, and interleukin] within 2 weeks before the first dose).
  • Prior radiation therapy, including palliative stereotactic radiation with abdominal, within 4 weeks before the first dose of study drug (if palliative stereotactic radiation therapy without abdominal, within 2 weeks)
  • Undergone major surgery (not including diagnostic surgery) within 4 weeks before the first dose of study drug or expect major surgery during the study
  • Undergone hematopoietic stem cell transplantation (HSCT) before the first dose of study drug, or autologous HSCT within 3 months before the first dose of study drug
  • Received systemic (>10 mg/day of prednisone or its equivalent) or other therapy within 2 weeks before the first dose of study drug. Received any within 4 weeks before the first dose of study drug or intend to receive a live vaccine during the study
  • Known (HIV) infection
  • Active virus (HBV) or virus (HCV) infection. Active HBV is defined as hepatitis B core antibody (HBcAb) or hepatitis B surface antigen (HBsAg) positive, and HBV DNA level above at the study site; active HCV is defined as positive hepatitis C antibody and HCV RNA level above ULN at the study site
  • Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia and pigmentation) not yet resolved to Grade ≤1, baseline, or the level specified in the inclusion/exclusion criteria. Patients with chronic Grade 2 toxicities who are asymptomatic or adequately managed with stable medication may be enrolled after discussion with the sponsor
  • A history of severe reactions to the drug substances, inactive ingredients in the drug product, or other mAbs
  • Women who are breastfeeding or pregnant as confirmed by pregnancy tests performed within 7 days before the first dose
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
312 participants (estimated)

Study arms

  • Experimental
    Dose escalation

    All participants enrolled in the dose escalation part

    Drug: YL201

  • Experimental
    Dose expansion

    All participants enrolled in the dose expansion part

    Drug: YL201

  • Experimental
    Dose Selection

    Drug: YL201 and atezolizumab

Interventions

  • DrugYL201

    Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.

  • DrugYL201

    Patients will be treated with YL201 intravenous (IV) (A mg/kg or B g/kg infusion once every 3 weeks (Q3W) as a cycle.

  • DrugYL201 and atezolizumab

    Drug pages: Tambotatug pelitecan · Atezolizumab

    Patients will be treated with YL201 intravenous (IV) infusion (A mg/kg or B mg/kg, up to 200mg) followed by atezolizumab on day 1 of each 21 day cycle

06

What researchers measure

Primary outcomes

  1. Evaluate the occurrence of DLTs during the first cycle in Part 1

    Time frame: 21 days of Cycle 1

  2. Evaluate the AEs in Part 2 as characterized by type, frequency, severity, timing, seriousness and relationship to study treatment

    Time frame: By the global end of trial date, approximately within 36 months

  3. Evaluate the prostate-specific antigen (PSA) response rate for patients with prostate cancer in Part 2

    PSA response rate: defined as the proportion of patients who achieved a ≥50% decrease in PSA from baseline

    Time frame: Approximately within 36 months

  4. Evaluate the objective response rate (ORR) for patients with solid tumors other than prostate cancer in Part 2, assessed using RECIST version 1.1

    ORR: defined as the proportion of patients who achieved a best overall response of complete response (CR) or partial response (PR).

    Time frame: Approximately within 36 months

  5. Laboratory abnormalities as characterized by type, frequency, severity, and timing in Part 2

    Time frame: Biy the end of trial date, approximately within 36 months

  6. Incidence, nature, and severity of AEs graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V5.0 in Part 3

    Time frame: Biy the end of trial date, approximately within 36 months

  7. Nature and frequency of dose-limiting toxicities (DLTs), incidence, nature, and severity of laboratory abnormalities in Part 3

    Time frame: At the end of cycle 1 (each cycle is 21 days)

Secondary outcomes

  1. Evaluate the AEs in Part 1 as characterized by type, frequency, severity, timing, seriousness and relationship to study treatment

    Time frame: By the global end of trial date, approximately within 36 months

  2. Characterize the PK parameter AUC

    Time frame: Approximately within 36 months

  3. Characterize the PK parameter Cmax

    Time frame: Approximately within 36 months

  4. Characterize the PK parameter Ctrough

    Time frame: Approximately within 36 months

  5. Characterize the PK parameter CL

    Time frame: Approximately within 36 months

  6. Characterize the PK parameter Vd

    Time frame: Approximately within 36 months

  7. Characterize the PK parameter t1/2

    Time frame: Approximately within 36 months

  8. Assess the incidence of anti-YL201 antibodies

    Time frame: Approximately within 36 months

  9. Evaluate the prostate-specific antigen (PSA) response rate for patients with prostate cancer in Part 1

    PSA response rate: defined as the proportion of patients who achieved a ≥50% decrease in PSA from baseline

    Time frame: Approximately within 36 months

  10. Evaluate the PSA progression-free survival (PSA-PFS) for patients with prostate cancer

    PSA-PFS: defined as the time interval from the date of the first dose of study drug to the date of the first documentation of PSA progression, based on PCWG3 criteria.

    Time frame: Approximately within 36 months

  11. Evaluate the radiological PFS (rPFS) for patients with prostate cancer

    rPFS: defined as the time interval from the date of the first dose of study drug to the date of the first documentation of radiographic tumor progression or death due to any cause, whichever occurs first, based on RECIST 1.1 and PCWG3 criteria.

    Time frame: Approximately within 36 months

  12. Evaluate the failure-free survival (FFS) for patients with prostate cancer

    FFS: defined as the time interval from the date of the first dose of study drug to the date of the first documentation of radiographic tumor progression, unequivocal clinical progression, PSA progression or death due to disease progression, whichever occurs first.

    Time frame: Approximately within 36 months

  13. Evaluate the objective response rate (ORR) for patients with solid tumors other than prostate cancer in Part 1, Part 2, and Part 3, assessed using RECIST version 1.1

    ORR: defined as the proportion of patients who achieved a best overall response of complete response (CR) or partial response (PR).

    Time frame: Approximately within 36 months

  14. Evaluate the disease control rate (DCR) for patients with solid tumors other than prostate cancer, assessed using RECIST version 1.1

    DCR: defined as the proportion of patients who achieved a best overall response of CR, PR or stable disease (SD).

    Time frame: Approximately within 36 months

  15. Evaluate the duration of response (DoR) for patients with solid tumors other than prostate cancer, assessed using RECIST version 1.1

    DoR: defined as the time interval from the date of the first documentation of objective response (CR or PR) to the date of the first documentation of PD. DoR will be assessed for patients with a response (CR or PR) only.

    Time frame: Approximately within 36 months

  16. Evaluate the time to response (TTR) for patients with solid tumors other than prostate cancer, assessed using RECIST version 1.1

    TTR: defined as the time interval from the date of the first dose of study drug to the date of the first documentation of objective response (CR or PR).

    Time frame: Approximately within 36 months

  17. Evaluate the progression-free survival (PFS) for patients with solid tumors other than prostate cancer, assessed using RECIST version 1.1

    PFS: defined as the time interval from the date of the first dose of study drug to the date of first documentation of PD or death due to any cause, whichever occurs first.

    Time frame: Approximately within 36 months

  18. Evaluate the overall survival (OS) for patients with solid tumors

    OS: defined as the time interval from the date of the first dose of study drug to the date of death due to any cause.

    Time frame: Approximately within 36 months

07

Study locations

38 of 45 sites recruiting
  • 002
    Fair Oaks, California 95628, United States
    Recruiting
    • Study Coordinator · Contact
  • 001
    La Jolla, California 92093-0698, United States
    Recruiting
    • Study Coordinator · Contact
  • 003
    Lone Tree, Colorado 80124, United States
    Recruiting
    • Study Coordinator · Contact
  • 004
    Washington D.C., District of Columbia 20007, United States
    Recruiting
    • Study Coordinator · Contact
  • 005
    Boston, Massachusetts 02114, United States
    Recruiting
    • Study Coordinator · Contact
  • 006
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Study Coordinator · Contact
  • 007
    Detroit, Michigan 48292, United States
    Recruiting
    • Study Coordinator · Contact
  • 008
    St Louis, Missouri 63110, United States
    Recruiting
    • Study Coordinator · Contact
  • 009
    Santa Fe, New Mexico 87505-699, United States
    Recruiting
    • Study Coordinator · Contact
  • 010
    New York, New York 10029, United States
    Recruiting
    • Study Coordinator · Contact
  • 011
    Chapel Hill, North Carolina 27514, United States
    Recruiting
    • Study Coordinator · Contact
  • 012
    Nashville, Tennessee 37203, United States
    Recruiting
    • Study Coordinator · Contact
  • 014
    Houston, Texas 77030, United States
    Recruiting
    • Site Coordinator · Contact
  • 015
    Irving, Texas 75039, United States
    Recruiting
    • Study Coordinator · Contact
  • 013
    San Antonio, Texas 78229, United States
    Recruiting
    • Site Coordinator · Contact
  • 016
    Tyler, Texas 75701, United States
    Recruiting
    • Study Coordinator · Contact
  • 017
    Fairfax, Virginia 22031, United States
    Recruiting
    • Study Coordinator · Contact
  • 018
    Spokane, Washington 99208, United States
    Recruiting
    • Study Coordinator · Contact
  • 019
    Tacoma, Washington 98405, United States
    Recruiting
    • Study Coordinator · Contact
  • 020
    Edmonton, Alberta T6G 1Z2, Canada
    Recruiting
    • Study Coordinator · Contact
  • 021
    Kelowna, British Columbia V1Y 1E2, Canada
    Recruiting
    • Study Coordinator · Contact
  • 022
    Brampton, Ontario L6R 3J7, Canada
    Recruiting
    • Study Coordinator · Contact
  • 023
    Toronto, Ontario M5G 2C4, Canada
    Recruiting
    • Study Coordinator · Contact
  • 024
    Guangzhou, Guangdong 510000, China
    Completed

    Not enrolling at this site — choose another above.

  • 025
    Zhengzhou, Henan 450003, China
    Completed

    Not enrolling at this site — choose another above.

  • 026
    Bordeaux, 33000, France
    Recruiting
    • Study Coordinator · Contact
  • 027
    Dijon, 21000, France
    Recruiting
    • Study Coordinator · Contact
  • 028
    Marseille, 13005, France
    Recruiting
    • Study Coordinator · Contact
  • 029
    Nantes, 44093, France
    Not yet recruiting
    • Study Coordinator · Contact
  • 030
    Paris, 75248, France
    Not yet recruiting
    • Study Coordinator · Contact
  • 031
    Poitiers, 86021, France
    Recruiting
    • Study Coordinator · Contact
  • 032
    Saint-Herblain, 44800, France
    Not yet recruiting
    • Study Coordinator · Contact
  • 033
    Suresnes, 92150, France
    Recruiting
    • Study Coordinator · Contact
  • 044
    Otwock, 05-400, Poland
    Recruiting
    • Study Coordinator · Contact
  • 045
    Poznan, 60-569, Poland
    Not yet recruiting
    • Study Coordinator · Contact
  • 034
    Barcelona, Barcelona 08023, Spain
    Recruiting
    • Study Coordinator · Contact
  • 035
    Barcelona, Barcelona 08025, Spain
    Recruiting
    • Study Coordinator · Contact
  • 039
    Leganés, Madrid 28911, Spain
    Not yet recruiting
    • Study Coordinator · Contact
  • 037
    Madrid, Madrid 28034, Spain
    Recruiting
    • Study Coordinator · Contact
  • 036
    Madrid, Madrid 28050, Spain
    Recruiting
    • Study Coordinator · Contact
  • 038
    Moncloa-Aravaca, Madrid 28040, Spain
    Recruiting
    • Study Coordinator · Contact
  • 041
    Pozuelo de Alarcón, Madrid 28223, Spain
    Recruiting
    • Study Coordinator · Contact
  • 042
    Usera, Madrid 28041, Spain
    Recruiting
    • Study Coordinator · Contact
  • 040
    Pamplona, Navarre 31008, Spain
    Recruiting
    • Study Coordinator · Contact
  • 043
    Valencia, Valencia 46010, Spain
    Recruiting
    • Study Coordinator · Contact
08

References and documents

Publications

  • Ma Y, Yang Y, Huang Y, Fang W, Xue J, Meng X, Fan Y, Fu S, Wu L, Zheng Y, Liu J, Liu Z, Zhuang W, Rosen S, Qu S, Li B, Li M, Zhao Y, Yang S, Ji Y, Sommerhalder D, Luo S, Yang K, Li J, Lv D, Zhang P, Zhao Y, Hong S, Zhang Y, Zhao S, Chin S, Zhang X, Lian W, Cai J, Xue T, Zhang L, Zhao H. A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial. Nat Med. 2025 Jun;31(6):1949-1957. doi: 10.1038/s41591-025-03600-2. Epub 2025 Mar 13. PubMed 40082695 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for Apr 2027, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2022
First posted
Jun 27, 2022
StartActual
May 25, 2022
Primary completionEst.
Apr 6, 2027
CompletionEst.
Oct 6, 2027
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05434234
Responsible party
Sponsor
First posted
Jun 27, 2022
Start date
May 25, 2022
Primary completion
Apr 6, 2027 (estimated)
Completion
Oct 6, 2027 (estimated)
Last update
Jun 22, 2026

Study contacts

Sasha Stann
Contact
info@medilinkthera.com
617-240-8494
Alan Xu, Ph.D.
Contact
info@medilinkthera.com
617-871-9455

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tambotatug pelitecan · Atezolizumab

Start the discussion